Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences announced promising results from their study of intranasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS), demonstrating a significant reduction in brain inflammation after three months. The breakthrough therapy, which modulates immune cells through a novel nasal delivery system, is paving the way for a new treatment avenue for neuroinflammatory conditions. These findings, supported by neuroimaging and clinical symptom assessments, are part of ongoing research to enhance the efficacy and safety of immunotherapies.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
